Using bioluminescence to monitor treatment response in real time in mice with mycobacterium ulcerans infection

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 1, 2011, Pages 56-61

  Zhang, Tianyu ^a   Li, Si Yang ^a   Converse, Paul J ^a   Almeida, Deepak V ^a   Grosset, Jacques H ^a   Nuermberger, Eric L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KANAMYCIN; RIFAMPICIN; STREPTOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL VIRULENCE; BIOENGINEERING; BIOLUMINESCENCE; BURULI ULCER; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; FOOT PAD; GENE; GENE EXPRESSION; IN VIVO STUDY; LUXAB GENE; MONOTHERAPY; MOUSE; MYCOBACTERIUM ULCERANS; NONHUMAN; PRIORITY JOURNAL; VIBRIO HARVEYI;

ANIMALS; ANTI-BACTERIAL AGENTS; BURULI ULCER; FEMALE; KANAMYCIN; LUMINESCENCE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM ULCERANS; RIFAMPIN; STREPTOMYCIN;

EID: 78650673813     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01260-10     Document Type: Article

References (23)

1. Addo, P., E. Owusu, B. Adu-Addai, M. Quartey, M. Abbas, A. Dodoo, and D. Ofori-Adjei. 2005. Findings from a buruli ulcer mouse model study. Ghana Med. J. 39:86-93.
2. Bentoucha, A., J. Robert, H. Dega, N. Lounis, V. Jarlier, and J. Grosset. 2001. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 45:3109-3112.
3. Berger, F., R. Paulmurugan, S. Bhaumik, and S. S. Gambhir. 2008. Uptake kinetics and biodistribution of 14C-D-luciferin-a radiolabeled substrate for the firefly luciferase catalyzed bioluminescence reaction: impact on bioluminescence based reporter gene imaging. Eur. J. Nucl. Med. Mol. Imaging 35:2275-2285.
4. Chauty, A., M. F. Ardant, A. Adeye, H. Euverte, A. Guèdè enon, C. Johnson, J. Aubry, E. Nuermberger, and J. Grosset. 2007. Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob. Agents Chemother. 51:4029-4035.
5. Davis, S. L., N. A. Be, G. Lamichhane, S. Nimmagadda, M. G. Pomper, W. R. Bishai, and S. K. Jain. 2009. Bacterial thymidine kinase as a non-invasive imaging reporter for Mycobacterium tuberculosis in live animals. PLoS One 4:e6297.
6. Dega, H., J. Robert, P. Bonnafous, V. Jarlier, and J. Grosset. 2000. Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob. Agents Chemother. 44:2367-2372.
7. Etuaful, S., B. Carbonnelle, J. Grosset, S. Lucas, C. Horsfield, R. Phillips, M. Evans, D. Ofori-Adjei, E. Klustse, J. Owusu-Boateng, G. K. Amedofu, P. Awuah, E. Ampadu, G. Amofah, K. Asiedu, and M. Wansbrough-Jones. 2005. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob. Agents Chemother. 49:3182-3186.
8. George, K. M., D. Chatterjee, G. Gunawardana, D. Welty, J. Hayman, R. Lee, and P. L. Small. 1999. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 283:854-857.
9. George, K. M., L. Pascopella, D. M. Welty, and P. L. Small. 2000. A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect. Immun. 68:877-883.
10. Heuts, F., B. Carow, H. Wigzell, and M. E. Rottenberg. 2009. Use of noninvasive bioluminescent imaging to assess mycobacterial dissemination in mice, treatment with bactericidal drugs and protective immunity. Microbes Infect. 11:1114-1121.
11. Ji, B., A. Chauffour, J. Robert, and V. Jarlier. 2008. Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob. Agents Chemother. 52:1912-1916.
12. Kibadi, K., M. Boelaert, A. G. Fraga, M. Kayinua, A. Longatto-Filho, J. B. Minuku, J. B. Mputu-Yamba, J. J. Muyembe-Tamfum, J. Pedrosa, J. J. Roux, W. M. Meyers, and F. Portaels. 2010. Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli ulcer (Mycobacterium ulcerans disease). PLoS Negl. Trop. Dis. 4:e736.
13. Lefrançois, S., J. Robert., A. Chauffour, B. Ji, and V. Jarlier. 2007. Curing Mycobacterium ulcerans infection in mice with a combination of rifampinstreptomycin or rifampin-amikacin. Antimicrob. Agents Chemother. 51:645-650. (Pubitemid 46185285)
14. Nienhuis, W. A., Y. Stienstra, W. A. Thompson, P. C. Awuah, K. M. Abass, W. Tuah, N. Y Awua-Boateng, E. O. Ampadu, V. Siegmund, J. P. Schouten, O. Adjei, G. Bretzel, and T. S. van der Werf. 2010. Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet 375:664-672.
15. Pidot, S. J., H. Hong, T. Seemann, J. L. Porter, M. J. Yip, A. Men, M. Johnson, P. Wilson, J. K. Davies, P. F. Leadlay, and T. P. Stinear. 2008. Deciphering the genetic basis for polyketide variation among mycobacteria producing mycolactones. BMC Genomics 9:462.
16. Phillips, R., F. S. Sarfo, L. Guenin-Macé, J. Decalf, M. Wansbrough-Jones, M. L. Albert, and C. Demangel. 2009. Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J. Infect. Dis. 200:1675-1684.
17. Portaels, F., M. T. Silva, and W. M. Meyers. 2009. Buruli ulcer. Clin. Dermatol. 27:291-305.
18. Rosseels, V., V. Roupie, D. Zinniel, R. G. Barletta, and K. Huygen. 2006. Development of luminescent Mycobacterium avium subsp. Paratuberculosis for rapid screening of vaccine candidates in mice. Infect. Immun. 74:3684-3686.
19. Shepard, C. C. 1969. Further experience with the kinetic method for the study of drugs against Mycobacterium leprae in mice. Activities of DDS, DFD, ethionamide, capreomycin and PAM 1392. Int. J. Lepr. Other Mycobact. Dis. 37:389-397.
20. Snewin, V. A., M. P. Gares, P. O. Gaora, Z. Hasan, I. N. Brown, and D. B. Young. 1999. Assessment of immunity to mycobacterial infection with luciferase reporter constructs. Infect. Immun. 67:4586-4593.
21. Tyagi, S., E. Nuermberger, T. Yoshimatsu, K. Williams, I. Rosenthal, N. Lounis, W. Bishai, and J. Grosset. 2005. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49:2289-2293.
22. World Health Organization. 2007. Global plan to combat neglected tropical diseases, 2008-2015. http://whqlibdoc.who.int/hq/2007/WHO-CDS-NTD-2007.3-eng. pdf.
23. Zhang, T., W. R. Bishai, J. H. Grosset, and E. L. Nuermberger. 2010. Rapid assessment of antibacterial activity against Mycobacterium ulcerans using recombinant luminescent strains. Antimicrob. Agents Chemother. 54:2806-2813.